Those of us who work in clinical operations and oncology drug development can sometimes get caught up in the operations or science and lose sight of the impact our work can have on the lives of people battling cancer. I’d like to share one man’s story to illustrate
Over the last decade, increased competition for finite patient populations in the U.S. have led many drug developers to expand…
In this interview, conducted by Keystone Marketing's Scott Broady, Denise Deakin, Co-Founder & President of Scimega Oncology answers questions about…
With the volume of medical data doubling every 5 years, the challenge has now become how to derive actionable insights…
Back in June of 2011, a leading U.S. biotech company, currently developing multiple therapeutic candidates, was planning a Phase I/II…
Like patient consent forms, site Clinical Trial Agreements (CTA) have become increasingly complex, making their review a major roadblock to…